Clinical Trial Update: Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on the safety and efficacy of allogeneic HPV-specific T cells in adults with recurrent or metastatic HPV-16-associated cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv-16-associated Cancers

Drugs mentioned

• Allogeneic HPV-specific T cells (HPV-specific allogeneic T cells)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: HPV 16+ Recurrent or Metastatic Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING